Medtronic plc

NYSE:MDT

Medical - Devices

Healthcare
$100.72 +0.96%

+$0.75 today

Market cap
$128.84B
Beta
0.60
P/E (TTM)
21.1
EPS (TTM)
$3.74
Dividend yield
3.60%
52W Low $73.31High $106.33

Volume 6.47M

Average 11.36M

MDT Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Medtronic plcNYSE: MDT

Stock-Based Compensation · Q1 FY2027 · quarter ended Jul 2026

Stock-based compensation growth accelerates

Q1 FY2027 stock-based compensation of $125M rose 45.3% year over year, ahead of the +14.8% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 31.6% from the prior quarter. Over 3 fiscal years it compounded at +8.8% a year.

Context

  • Stock-based compensation amounted to 1.3% of revenue in FY2026, unchanged from a year earlier.
  • Stock-based compensation increased in 3 of the last 3 fiscal years.
  • FY2026 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +45.3% holds above the trailing-twelve-month pace of +14.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJul 2026
$125M+31.6% QoQ
Last fiscal yearApr 2026
$457M+6.5% YoY
LTMJul 2026
$496M+14.8% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+45.3%——
1 year+6.5%——
3-year CAGR+8.8%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2026
457M USD
Year-over-year change
+6.5%
4-year CAGR
+6.2%

Stock-Based Compensation vs competitors

How MDT compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +14.8% is the 3rd highest of 9, against a peer median of +7.7%.
  • Stock-based compensation amounts to 1.3% of revenue for MDT, versus a peer median of 1.9%.
MDT Competitors
Stock-Based Compensation for MDT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MDTMedtronic plcLTM Jul 2026$496M USD+14.8%+8.8%1.3%
SYKStryker CorporationLTM Jun 2026$251M USD+9.6%+13.1%1.0%
EWEdwards Lifesciences CorporationLTM Jun 2026$168M USD-1.5%+7.6%2.6%
BSXBoston Scientific CorporationLTM Jun 2026$166M USD+5.7%+10.8%0.8%
PHGKoninklijke Philips N.V.LTM Jun 2026€112M EUR-17.6%—0.6%
ZBHZimmer Biomet Holdings, Inc.LTM Jun 2026$98.2M USD+13.7%-4.9%1.2%
PENPenumbra, Inc.LTM Jun 2026$59.5M USD+16.5%—4.0%
LIVNLivaNova PLCLTM Sep 2026$49.04M USD+44.9%-6.8%3.3%
AVRAnteris Technologies Global Corp.LTM Mar 2026$4.48M USD-15.1%+38.4%241.9%
Peer median (excluding MDT) —+7.7%+9.2%1.9%

Competitors are the stored peer set for MDT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Apr 2022
FY2023
Apr 2023
FY2024
Apr 2024
FY2025
Apr 2025
FY2026
Apr 2026
Net Income5.06B3.78B3.68B4.69B4.84B
Depreciation & Amortization2.71B2.7B2.65B2.86B2.96B
Deferred Income Tax(604M)(226M)(508M)(316M)51M
Stock-Based Compensation359M355M393M429M457M
Change in Working Capital(889M)(967M)(484M)(1.05B)(1.42B)
Accounts Receivables(477M)(576M)(391M)(433M)(200M)
Inventory(560M)(939M)(139M)(292M)(404M)
Accounts Payables213M696M391M209M46M
Other Working Capital(65M)(148M)(345M)(538M)(865M)
Other Non-Cash Items711M396M1.06B433M450M
Operating Cash Flow7.35B6.04B6.79B7.04B7.33B
Capital Expenditures(1.37B)(1.46B)(1.59B)(1.86B)(1.9B)
Acquisitions (Net)(91M)(1.87B)(211M)(98M)(406M)
Purchases of Investments(9.88B)(7.51B)(7.75B)(8.23B)(8.73B)
Sales of Investments9.69B7.34B7.44B8.5B8.11B
Other Investing Activities(10M)4M(261M)(249M)(4M)
Investing Cash Flow(1.66B)(3.49B)(2.37B)(1.94B)(2.93B)
Debt Repayment(1M)(598M)1.07B2.14B(1.17B)
Common Stock Issued429M308M284M508M516M
Common Stock Repurchased(2.54B)(645M)(2.14B)(3.24B)(1.04B)
Dividends Paid(3.38B)(3.62B)(3.67B)(3.59B)(3.64B)
Other Financing Activities163M(101M)(3M)(184M)582M
Financing Cash Flow(5.34B)(4.96B)(4.45B)(4.36B)(4.75B)
Effect of Forex Changes(230M)243M(230M)188M85M
Net Change in Cash121M(2.17B)(259M)934M(269M)
Free Cash Flow5.98B4.58B5.2B5.19B5.43B

Medtronic plc

NYSE:MDT

Intrinsic Alpha fair value

Locked

Current Price

$100.72

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.